Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia
- PMID: 22654759
- PMCID: PMC3361072
- DOI: 10.3389/fphar.2012.00101
Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia
Abstract
The cannabinoid receptor 1 (CB1R) is the G-protein coupled receptor responsible for the majority of the endocannabinoid signaling in the human brain. It is widely distributed in the limbic system, basal ganglia, and cerebellum, which are areas responsible for cognition, memory, and motor control. Because of this widespread distribution, it is not surprising that drugs that activate CB1R have expected behavioral outcomes consistent with dysregulated signaling from these areas (e.g., memory loss, cognitive deficits, etc). In the context of this review, we present evidence for the role of CB1R signaling in the prefrontal cortex (PFC), an area involved in executive functions, with emphasis on the developmental regulation of CB1R signaling in the acquisition of mature PFC function. We further hypothesize how alterations in CB1R signaling specifically during adolescent maturation might confer liability to psychiatric disorders.
Keywords: adolescence; cannabinoids; prefrontal cortex; schizophrenia.
Figures

Similar articles
-
Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia.Transl Psychiatry. 2020 May 19;10(1):158. doi: 10.1038/s41398-020-0832-8. Transl Psychiatry. 2020. PMID: 32433545 Free PMC article.
-
Laminar Distribution of Cannabinoid Receptor 1 in the Prefrontal Cortex of Nonhuman Primates.Mol Neurobiol. 2024 Jul;61(7):1-12. doi: 10.1007/s12035-023-03828-4. Epub 2023 Dec 7. Mol Neurobiol. 2024. PMID: 38062346
-
The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.Biol Psychiatry. 2016 Apr 1;79(7):595-603. doi: 10.1016/j.biopsych.2015.06.015. Epub 2015 Jun 19. Biol Psychiatry. 2016. PMID: 26210060 Free PMC article. Review.
-
Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study.Neurobiol Dis. 2023 Sep;185:106262. doi: 10.1016/j.nbd.2023.106262. Epub 2023 Aug 15. Neurobiol Dis. 2023. PMID: 37586566 Free PMC article.
-
Basic neuroanatomy and neuropharmacology of cannabinoids.Int Rev Psychiatry. 2009 Apr;21(2):113-21. doi: 10.1080/09540260902782760. Int Rev Psychiatry. 2009. PMID: 19367505 Review.
Cited by
-
Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study.BMC Psychiatry. 2024 Sep 27;24(1):626. doi: 10.1186/s12888-024-06075-6. BMC Psychiatry. 2024. PMID: 39334053 Free PMC article.
-
Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.Neurol Clin Pract. 2015 Aug;5(4):344-351. doi: 10.1212/CPJ.0000000000000162. Neurol Clin Pract. 2015. PMID: 26336632 Free PMC article.
-
BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction.Hum Mol Genet. 2017 Jul 1;26(13):2462-2471. doi: 10.1093/hmg/ddx139. Hum Mol Genet. 2017. PMID: 28402427 Free PMC article.
-
Mechanisms contributing to cognitive deficits in cannabis users.Neuropharmacology. 2017 Sep 15;124:84-88. doi: 10.1016/j.neuropharm.2017.04.018. Epub 2017 Apr 14. Neuropharmacology. 2017. PMID: 28414051 Free PMC article. Review.
-
Marijuana: current concepts(†).Front Public Health. 2013 Oct 10;1:42. doi: 10.3389/fpubh.2013.00042. Front Public Health. 2013. PMID: 24350211 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous